Givosiran - Alnylam Pharmaceuticals

Drug Profile

Givosiran - Alnylam Pharmaceuticals

Alternative Names: ALN-AS1

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Oligonucleotides; Pyrrolidines; Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute intermittent porphyria

Most Recent Events

  • 02 Aug 2018 Alnylam Pharmaceuticals anticipates to launch givosiran in Acute intermittent porphyria in 2019, assuming regulatory approvals
  • 03 May 2018 Alnylam Pharmaceuticals announces intention to submit MAA to the EMA for Acute intermittent porphyria in 2019
  • 23 Apr 2018 Alnylam Pharmaceuticals plans a phase I trial for Acute Intermittent Porphyria in Sweden , (NCT03505853)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top